Xalud Ther­a­peu­tics pri­or­i­tizes gene ther­a­pies, with ALS now the fo­cus and os­teoarthri­tis on part­ner path 

Xalud Ther­a­peu­tics has shift­ed its in­ter­nal plans, send­ing its lead non-vi­ral gene ther­a­py on the part­ner­ing path, el­e­vat­ing a pre­clin­i­cal ALS pro­gram and let­ting em­ploy­ees …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER